<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00609791</url>
  </required_header>
  <id_info>
    <org_study_id>07157</org_study_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-07157</secondary_id>
    <secondary_id>ABRAXIS-ABX206-BC07US</secondary_id>
    <secondary_id>CDR0000586461</secondary_id>
    <secondary_id>NCI-2011-02403</secondary_id>
    <nct_id>NCT00609791</nct_id>
  </id_info>
  <brief_title>Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer</brief_title>
  <official_title>Age-Related Changes in Nanoparticle Albumin Bound (Nab) Paclitaxel Pharmacokinetics and Pharmacodynamics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Gathering information from patients of different ages receiving paclitaxel&#xD;
      albumin-stabilized nanoparticle formulation for metastatic breast cancer may help doctors&#xD;
      understand how the age of the patient changes the way the drug works.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well paclitaxel albumin-stabilized nanoparticle&#xD;
      formulation works in treating patients of different ages with metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine age-related changes in the pharmacokinetics (pK) of weekly paclitaxel&#xD;
           albumin-stabilized nanoparticle formulation (nab-paclitaxel) in patients with metastatic&#xD;
           breast cancer.&#xD;
&#xD;
        -  To determine age-related changes in the pharmacodynamics (toxicity) of nab-paclitaxel in&#xD;
           these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine response and time to progression in these patients.&#xD;
&#xD;
        -  To explore predictors of pK parameters in these patients.&#xD;
&#xD;
        -  To explore predictors of the need for dose reduction, dose delays, or grade 3 or 4&#xD;
           toxicity in these patients.&#xD;
&#xD;
      OUTLINE: Patients are stratified by age in years (&lt; 50 vs 50-60 vs 60-70 vs &gt; 70).&#xD;
&#xD;
      Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes&#xD;
      once daily on days 1, 8, and 15 as planned. Treatment repeats every 28 days in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Blood is drawn for pharmacokinetic studies periodically during course 1.&#xD;
&#xD;
      Patients complete questionnaires regarding risk factors that would predict for&#xD;
      pharmacokinetic parameters at baseline, prior to the third course of treatment, and at end of&#xD;
      study. Data collected include medical characteristics, demographics, functional status,&#xD;
      comorbidity, psychological status, social functioning and support, nutritional status, and&#xD;
      cognition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 25, 2008</start_date>
  <completion_date type="Anticipated">December 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 25, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Age-related changes in the pharmacokinetics (pK)</measure>
    <time_frame>Cycle 1, week 1 at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Age-related changes in the pharmacodynamics (toxicity)</measure>
    <time_frame>Cycle 1, week 1 at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
    <time_frame>Assessed after every 2 cycles of therapy until progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>1 year after completion of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors of pK parameters</measure>
    <time_frame>After week 1 of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors of the need for dose reduction, dose delays, or grade 3 or 4 toxicity</measure>
    <time_frame>At the completion of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel albumin-stabilized nanoparticle formulation</intervention_name>
    <description>100 mg/m2 3 weeks on 1 week off</description>
    <arm_group_label>nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Cycle 1, week 1 at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hours</description>
    <arm_group_label>nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>physiologic testing</intervention_name>
    <description>Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy</description>
    <arm_group_label>nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy</description>
    <arm_group_label>nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>study of socioeconomic and demographic variables</intervention_name>
    <description>Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy</description>
    <arm_group_label>nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cognitive assessment</intervention_name>
    <description>Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy</description>
    <arm_group_label>nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>psychosocial assessment and care</intervention_name>
    <description>Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy</description>
    <arm_group_label>nab-paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Diagnosis of metastatic breast cancer&#xD;
&#xD;
          -  Any estrogen receptor, progesterone receptor, or HER-2/neu status allowed as long as&#xD;
             the patient will receive paclitaxel albumin-stabilized nanoparticle formulation alone&#xD;
&#xD;
          -  First- or second-line chemotherapy treatment for metastatic disease planned&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Untreated CNS metastases or symptomatic CNS metastases requiring escalating doses of&#xD;
             corticosteroids&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 70-100%&#xD;
&#xD;
          -  WBC ≥ 3,000/mm³&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN (unless bone metastases are present in the&#xD;
             absence of liver metastases)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Peripheral neuropathy ≤ grade 1&#xD;
&#xD;
          -  Creatinine clearance ≥ 30 mL/min (calculated or 24-hour)&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No known history of allergic reactions to paclitaxel&#xD;
&#xD;
          -  No serious or uncontrolled infection&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No ≥ grade 2 toxicity from prior therapy (other than alopecia)&#xD;
&#xD;
          -  No taxane for adjuvant therapy or metastatic disease within the past 12 months&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arti Hurria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Medical Group</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 6, 2008</study_first_submitted>
  <study_first_submitted_qc>February 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2008</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

